September 20, 2016—Yesterday we wrote about how The New York Times and the Center for Public Integrity exposed how drug companies co-opt patient-advocacy and civic groups with big donations. Some disease-awareness and civic groups, we noted, parrot negative pharmaceutical industry talking points about the 340B drug discount program. You can add Bloomberg Markets to the list of news organizations investigating the cozy relationship between drugmakers and patient advocates.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)